Skip to main content
Brian Till, MD, Oncology, Seattle, WA, Seattle Cancer Care Alliance

BrianGeraldTillMD

Oncology Seattle, WA

Hematologic Oncology

Assistant Professor, Medicine, University of Washington School of Medicine

Overview of Dr. Till

Dr. Brian Till is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance and UW Medicine/University of Washington Medical Center. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 15 years. Dr. Till accepts several types of health insurance, listed below. He is one of 173 doctors at Seattle Cancer Care Alliance and one of 143 doctors at UW Medicine/University of Washington Medical Center who specialize in Oncology. He has more than 60 publications and over 500 citings.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2005 - 2023
  • PA State Medical License
    PA State Medical License 2002 - 2005
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
    Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
    Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
    Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Press Mentions

  • Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
    Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Anthem HealthKeepers HMO/POS
    Anthem KeyCare PPO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    First Health PPO
    Great West PPO
    Health Net Oregon PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Premera BCBS Heritage & Heritage Plus 1
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment